Diagnosis and therapy of cancer using SGP28-related molecules
AssigneeAgensys, Inc.
InventorsRene Hubert, Arthur Raitano, Daniel Afar, Steve Mitchell, Mary Faris, Aya Jakobovits
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods and compositions for the diagnosis and therapy of prostate cancer which utilize isolated polynucleotides corresponding to the human SGP28 gene, proteins encoded by the SGP28 gene and fragments thereof, and antibodies capable of specifically recognizing and binding to SGP28 proteins.
Claims15
A method of detecting the presence of a cancer expressing SGP28 protein that comprises determining the level of SGP28 protein expressed by cells in a test tissue sample from an individual and comparing the level so determined to the level of SGP28 expressed in a corresponding normal sample, the presence of elevated SGP28 protein in the test sample relative to the normal sample providing an indication of the presence of such cancer in the individual.
A method of monitoring SGP28 gene products comprising determining the status of SGP28 gene products expressed by cells in a test tissue sample from an individual and comparing the status so determined to the status of SGP28 gene products in a corresponding normal sample, the presence of altered status of SGP28 gene products in the test sample relative to the normal sample providing an indication of dysregulated cell growth within the individual.
A method of examining a biological sample for evidence of dysregulated cellular growth comprising comparing the status of SGP28 in the biological sample to the status of SGP28 in a corresponding normal sample, wherein alterations in the status of SGP28 in the biological sample are associated with dysregulated cellular growth.
A method of diagnosing the presence of cancer in an individual comprising:
- (a) determining the level of SGP28 mRNA expressed in a test sample obtained from the individual;
- and
- (b) comparing the level so determined to the level of SGP28 mRNA expressed in a comparable known normal tissue sample, the presence of elevated SGP28 mRNA expression in the test sample relative to the normal tissue sample providing an indication of the presence of cancer.
A method of diagnosing the presence of cancer in an individual comprising:
- (a) determining the level of SGP28 protein expressed in a test sample obtained from the individual;
- and
- (b) comparing the level so determined to the level of SGP28 protein expressed in a comparable known normal tissue sample,
- the presence of elevated SGP28 protein in the test sample relative to the normal tissue sample providing an indication of the presence of cancer.
15-38. (canceled)
Dependencies are inferred from the claim text.